BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15693753)

  • 1. Multidrug-resistant cancer cells contain two populations of P-glycoprotein with differently stimulated P-gp ATPase activities: evidence from atomic force microscopy and biochemical analysis.
    Barakat S; Gayet L; Dayan G; Labialle S; Lazar A; Oleinikov V; Coleman AW; Baggetto LG
    Biochem J; 2005 Jun; 388(Pt 2):563-71. PubMed ID: 15693753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells.
    Gayet L; Dayan G; Barakat S; Labialle S; Michaud M; Cogne S; Mazane A; Coleman AW; Rigal D; Baggetto LG
    Biochemistry; 2005 Mar; 44(11):4499-509. PubMed ID: 15766280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of detergents on P-glycoprotein atpase activity: differences in perturbations of basal and verapamil-dependent activities.
    Orlowski S; Selosse MA; Boudon C; Micoud C; Mir LM; Belehradek J; Garrigos M
    Cancer Biochem Biophys; 1998 Jun; 16(1-2):85-110. PubMed ID: 9923970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells.
    Troost J; Lindenmaier H; Haefeli WE; Weiss J
    Mol Pharmacol; 2004 Nov; 66(5):1332-9. PubMed ID: 15308763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of multidrug resistance reversal agents with P-glycoprotein ATPase activity on blood-brain barrier.
    He L; Liu GQ
    Acta Pharmacol Sin; 2002 May; 23(5):423-9. PubMed ID: 11978192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of P-glycoprotein-mediated multidrug resistance by cholesterol derived from low density lipoprotein in a vinblastine-resistant human lymphoblastic leukemia cell line.
    Shu Y; Liu H
    Biochem Cell Biol; 2007 Oct; 85(5):638-46. PubMed ID: 17901905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux.
    Tainton KM; Smyth MJ; Jackson JT; Tanner JE; Cerruti L; Jane SM; Darcy PK; Johnstone RW
    Cell Death Differ; 2004 Sep; 11(9):1028-37. PubMed ID: 15131592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol-mediated activation of P-glycoprotein: distinct effects on basal and drug-induced ATPase activities.
    Belli S; Elsener PM; Wunderli-Allenspach H; Krämer SD
    J Pharm Sci; 2009 May; 98(5):1905-18. PubMed ID: 18937360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity.
    Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A
    Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal sphingomyelin influences the cellular lipid profile of human lymphoblastic leukemia cells without effect on P-glycoprotein activity.
    Zembruski NC; Nguyen CD; Theile D; Ali RM; Herzog M; Hofhaus G; Heintz U; Burhenne J; Haefeli WE; Weiss J
    Mol Pharm; 2013 Mar; 10(3):1020-34. PubMed ID: 23379426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of CJZ3, a lomerizine derivative, with ATPase activity of human P-glycoprotein in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Ji BS; Li M; He L
    Pharmazie; 2010 Jul; 65(7):515-9. PubMed ID: 20662321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity.
    Karwatsky J; Lincoln MC; Georges E
    Biochemistry; 2003 Oct; 42(42):12163-73. PubMed ID: 14567677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (+/-)-3'-O, 4'-O-dicynnamoyl-cis-khellactone, a derivative of (+/-)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells.
    Shen X; Chen G; Zhu G; Fong WF
    Bioorg Med Chem; 2006 Nov; 14(21):7138-45. PubMed ID: 16875827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane.
    Garrigues A; Escargueil AE; Orlowski S
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10347-52. PubMed ID: 12145328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of CJY, an isoflavone, with ATPase of P-glycoprotein in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Cen J; Liu L; He L; Ji BS
    Drug Res (Stuttg); 2013 Aug; 63(8):429-34. PubMed ID: 23720244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective modulation of P-glycoprotein-mediated drug resistance.
    Bebawy M; Morris MB; Roufogalis BD
    Br J Cancer; 2001 Dec; 85(12):1998-2003. PubMed ID: 11747345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential.
    Alemán C; Annereau JP; Liang XJ; Cardarelli CO; Taylor B; Yin JJ; Aszalos A; Gottesman MM
    Cancer Res; 2003 Jun; 63(12):3084-91. PubMed ID: 12810633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein.
    Garrigues A; Nugier J; Orlowski S; Ezan E
    Anal Biochem; 2002 Jun; 305(1):106-14. PubMed ID: 12018951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
    Chan KF; Zhao Y; Burkett BA; Wong IL; Chow LM; Chan TH
    J Med Chem; 2006 Nov; 49(23):6742-59. PubMed ID: 17154505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
    Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
    Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.